Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial - Annals of Oncology
1 RESPONSE TO THE PUBLICATION OF THE CLEOPATRA CLINICAL TRIAL PAPER Executive Summary If a patient does not take a treatment th
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study - The Lancet Oncology
HER2-positive advanced breast cancer treatment in 2020 - Cancer Treatment Reviews
Nadine Ezer Clinical Trial Monitor Roche - ppt download
Cleopatra trial
End-of-Study Results From CLEOPATRA - The ASCO Post
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer | NEJM
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer | NEJM
Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. | Semantic Scholar
PDF) Overview of the CLEOPATRA Trial: Implications for Advanced Practitioners
Summary of the CLEOPATRA, APHINITY, NeoSphere, and TRYPHAENA clinical... | Download Scientific Diagram
Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial - European Journal of Cancer
Confirmatory Overall Survival Analysis of CLEOPATRA | Research To Practice
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results - The Breast
Summary of the CLEOPATRA, APHINITY, NeoSphere, and TRYPHAENA clinical... | Download Scientific Diagram
Confirmatory Overall Survival Analysis of CLEOPATRA | Research To Practice
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study - The Lancet Oncology
CLEOPATRA Protocol review & OS 분석결과. Study Title A Phase III, Randomized, Double-Blind, Placebo- Controlled Clinical Trial to Evaluate the Efficacy and. - ppt download
Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial - European Journal of Cancer
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study - The Lancet Oncology
Pertuzumab with Trastuzumab and Docetaxel in Elderly Patients in the CLEOPATRA Study | Research To Practice
HER2 Therapies - HER2+ MBC - Module - HER2+ MBC Care - Oncology - Clinical Care Options
